Location History:
- Gwangju, KR (2003)
- Kwangju, KR (2001 - 2011)
- Seoul, KR (2004 - 2024)
Company Filing History:
7 out of 8 
3 out of 3 
2 out of 1,575 
Years Active: 2001-2024
Title: The Innovative Mind of Youngro Byun: A Pioneer in Doppel-Targeting Molecules
Introduction
Youngro Byun, an accomplished inventor based in Seoul, South Korea, has made significant contributions to the field of biomedical research. With an impressive portfolio of 12 patents, Byun is recognized for his innovative work in developing doppel-targeting antibodies that hold promise for treating various pathological conditions.
Latest Patents
Youngro Byun's latest patents focus on the development of doppel-targeting molecules, particularly antibodies that inhibit pathological angiogenesis. This groundbreaking work is crucial in the treatment of diseases associated with pathological angiogenesis, including tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), and other neoplastic conditions. Byun provides detailed methodologies for detecting doppel expression in subjects and describes related compositions and methods, aiming to enhance therapeutic approaches in the biomedical field.
Career Highlights
Throughout his career, Youngro Byun has worked with esteemed companies in the healthcare and biotechnology sectors. Notably, he served at Mediplex Corporation and Pharosgen Co., Ltd., where he honed his expertise in innovative therapeutic solutions. His extensive experience and commitment to research positioned him among the leaders in developing advanced biomedical technologies.
Collaborations
In pursuing his innovative research, Youngro Byun has collaborated with talented individuals such as Sang-Yoon Kim and Yong-Kyu Lee. These partnerships emphasize a collaborative spirit within the scientific community, fostering creativity and innovation in addressing complex health challenges.
Conclusion
Youngro Byun's contributions to the field of doppel-targeting antibodies illustrate the potential of innovation in addressing critical medical issues. With his rich experience and collaborative efforts, he continues to pave the way for future advancements in biomedical research, reaffirming his status as a key inventor in the industry.